# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The investment is aimed at ensuring a steady supply of the drugs, which have been grappling with shortages since 2022.
This additional investment is part of the most ambitious manufacturing expansion agenda in the company's history. Since 202...
- Reuters
A new study predicts Elon Musk will become the world's first trillionaire if Tesla can regain the $1 trillion market cap le...
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight loss...
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The compan...
In QWINT-2, efsitora helped adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists achieve an A1...